NLRP3 and cryopyrin-associated periodic syndrome: Although most hyperactive NLRP3 variants tested in this study were sensitive to MCC950-mediated inhibition, it is important to take MCC950-insensitive variants into consideration while stratifying patients with CAPS for future clinical trials.